Clinical trial

A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus

NCT07347080

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Exenatide Circular RNA-Lipid Nanoparticle Injection（ CR059）） Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus

Design: INTERVENTIONAL · Status: RECRUITING · Phase: EARLY_PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2026-01-20

PhaseEARLY_PHASE1

Conditions

T2DMverified · MONDO: type 2 diabetes mellitus

Interventions

Exenatide Circular RNA-Lipid Nanoparticle Injection（ CR059））DRUG

Sponsors & collaborators

The First Affiliated Hospital of Henan University of Science and Technologylead sponsor

PegBio Co., Ltd.collaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07347080 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.